Abstract: Disclosed herein is a multi-channel device for detecting plasma at an ultra-fast speed, including: a first antenna module connected to a first output terminal in contact with a substrate on a chuck of a process chamber and extending to ground, and receiving a first leakage current leaking through the substrate to increase reception sensitivity of the leakage current; a first current detection module detecting the first leakage current; a current measurement module receiving the first leakage current output from the first current detection module, and extracting the received first leakage current for each predetermined period to generate a first leakage current measurement information; and a control module comparing the first leakage current measurement information with a reference value to generate first arcing occurrence information.

Abstract: Disclosed are a method and apparatus for reusing wastewater. The method for reusing wastewater disclosed herein includes: generating a mixed wastewater by mixing multiple types of wastewater (S20); performing a first purification by passing the mixed wastewater through a flocculation-sedimentation unit (S40); performing a second purification by passing an effluent of the flocculation-sedimentation unit through a membrane bioreactor (MBR) (S60); performing a third purification by passing an effluent of the MBR through a reverse-osmosis membrane unit (S80); and reusing an effluent of the reverse-osmosis membrane unit as cooling water or industrial water (S100).

Abstract: An electronic device including a touch-enabled display module configured to display a plurality of windows according to a multi-window mode; and a control module configured to displaying on the touch screen a first application window and a second application window according to the multi-window mode, alter the first application window in response to a touchscreen input received via the touch-enabled display, and automatically alter the second application window in response to the alteration of the first application window.

Abstract: A method of manufacturing a composite electrode for an all-solid-state battery includes: preparing a precursor solution by mixing at least one solid electrolyte precursor and at least one polar solvent; stirring the precursor solution; preparing an electrode slurry by adding an active material to the stirred precursor solution; and heat-treating the electrode slurry and obtaining the composite electrode for the all-solid-state battery, wherein the composite electrode for the all-solid-state battery includes: the active material; and a coating layer disposed on the active material and including a solid electrolyte.

Abstract: Provided is a peptide composition for preventing or treating Alzheimer's dementia. A peptide or a salt substituent thereof according to the presently claimed subject matter exhibits effects such as suppression of LPS-mediated cytokine production, suppression of LPS-induced neuroinflammation, amelioration of cognitive impairment, suppression of beta amyloid or tau protein aggregation, and suppression of neuronal loss. The polypeptide or the salt substituent thereof can permeate the blood-brain barrier, and thus, is expected to be usefully used for preventing or treating Alzheimer's dementia.

Abstract: The present disclosure relates to an electrode lead for an electrochemical device, including a nickel plating layer disposed on the surface of a metallic terminal, having a surface irregularity structure on the nickel plating layer, and including a polar group-containing coating layer. The present disclosure also relates to an electrochemical device including the electrode lead. The electrode lead for an electrochemical device provides increased binding force between the electrode lead and the lead film by increasing the contact area between the electrode lead and the lead film, while not causing damages upon the surface of the electrode lead.

Abstract: The present embodiment relates to a dual lens drive device that comprises: a housing; a first bobbin which is disposed to move in a first direction inside the housing; a second bobbin which is disposed to move in the first direction inside housing and is spaced apart from the first bobbin; a first coil which is disposed on the first bobbin; a second coil which is disposed on the second bobbin; a magnet which is disposed in the housing and faces the first coil and the second coil; a base which is disposed below the housing; a substrate which comprises a circuit member having a third coil disposed to face the magnet between the housing and the base; and a support member which movably supports the housing with respect to the substrate, wherein the housing is integrally formed.

Abstract: The present disclosure relates to a secondary battery. The secondary battery may include an electrode assembly including a plurality of positive electrode plates with each plate having a positive electrode tab, a plurality of negative electrode plates with each plate having a negative electrode tab, and a plurality of separators with each separator interposed between a positive electrode plate and a negative electrode plate, a case accommodating the electrode assembly, and a tab welding portion comprising welded overlapping positive electrode tabs and welded overlapping negative electrode tabs. A length of the tab welding portion in an extension direction of the positive electrode tab or the negative electrode tab may be constant or different across a thickness direction of the positive electrode tab or the negative electrode tab.

Abstract: A coil component is provided. The coil component includes a body having fifth and sixth surfaces opposing each other, first and second surfaces respectively connecting the fifth and sixth surfaces of the body and opposing each other, and third and fourth surfaces respectively connecting the first and second surfaces of the body and opposing each other in one direction, a recess disposed in an edge between one of the first and second surfaces of the body and the sixth surface of the body, a coil portion disposed inside the body and exposed through the recess, and an external electrode including a connection portion disposed in the recess and connected to the coil portion, and a pad portion disposed on one surface of the body. A length of the pad portion in the one direction is greater than a length of the connection portion in the one direction.

Abstract: A polishing composition and method for semiconductor processing being applicable to a semiconductor process including a process of polishing a semiconductor wafer including a through-silicon via (TSV), being capable of implementing excellent polishing performance, being capable of minimizing defects such as dishing, erosion, and protrusion, being capable of realizing an evenly polished surface without deviation between films when polishing a surface where a plurality of different films is exposed to the outside, including abrasive grains and at least one additive, and having a value of 1.45 to 1.90 as calculated by Equation 1.

Abstract: The present invention relates to a method for extracting collagen from a liposuction effluent, wherein collagen is extracted by treating a collagen-containing liposuction effluent in the presence of a supercritical fluid. According to the present invention, conventionally discarded collagen in a liposuction effluent can be extracted at high purity, and the extracted high purity collagen can be widely used in medical, pharmaceutical, and cosmetic products.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: Disclosed are a pharmaceutical composition containing isolated mitochondria as an effective component and uses of the composition. The pharmaceutical composition can restore the ATP synthesis capacity and antioxidant capacity of tenocytes damaged by inflammations to a normal tenocyte level. In addition, the pharmaceutical composition, when administered to damaged tenocytes, inhibits the expression of an apoptosis promoter, Bax, and increases the expression of an apoptosis inhibitor, Bcl-2. In addition, the pharmaceutical composition, when administered to damaged tenocytes, can restore the expression of MMP1 to a normal tenocyte level. Accordingly, uses of the pharmaceutical composition include prevention or treatment of tendinopathy in a subject.

Abstract: The present invention relates to a method for extracting collagen from liposuction effluent, wherein collagen is extracted by treating collagen-containing liposuction effluent in the presence of a supercritical fluid. According to the present invention, conventionally discarded collagen in liposuction effluent can be extracted at high purity, and the extracted high purity collagen can be widely used in medical, pharmaceutical, and cosmetic products.

Abstract: Mitochondria modified by a targeting protein, according to one embodiment of the present invention, can be effectively delivered to a target. In addition, when a protein of interest bound to the modified mitochondria is delivered into a cell, various activities can be exhibited. The modified mitochondria can effectively cause cancer tissue death, and thus can also be used as an anticancer agent. Furthermore, various activities are exhibited according to a protein of interest loaded on modified mitochondria, and thus the modified mitochondria can be applied in the treatment of various diseases. Additionally, a fusion protein comprising a protein of interest and a fusion protein comprising a targeting protein, according to one embodiment of the present invention, can be used in order to modify mitochondria. Moreover, mitochondria modified with the fusion proteins exhibits various effects in a target cell.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of rheumatoid arthritis and, more particularly, to a pharmaceutical composition comprising mitochondria as an effective ingredient for prevention or treatment of rheumatoid arthritis. When a foreign mitochondria pharmaceutical composition of the present invention is administered to a subject suffering from rheumatoid arthritis, the subject may alleviate edema and rubefaction symptoms. In addition, the pharmaceutical composition of the present invention reduces an expression level of the inflammatory cytokine IL-6, but increases an expression level of the anti-inflammatory cytokine IL-10 in the subject. Therefore, the pharmaceutical composition according to the present invention can be effectively used for preventing or treating rheumatoid arthritis.

Abstract: A ferroelectric semiconductor device of the present disclosure includes a substrate, a ferroelectric layer disposed on the substrate, an electric field control layer that is disposed on the ferroelectric layer and has a predetermined internal electric field formed without the application of an external electric power to alter the magnitude of a coercive electric field of the ferroelectric layer, and a gate electrode layer disposed on the electric field control layer.

Abstract: In an embodiment, a ferroelectric memory device includes a semiconductor substrate, a first ferroelectric memory cell transistor of NMOS type disposed in a first region of the semiconductor substrate, and a second ferroelectric memory cell transistor of PMOS type disposed in a second region adjacent to the first region of the semiconductor substrate. A first gate electrode layer of the first ferroelectric memory cell transistor and a second gate electrode layer of the second ferroelectric memory cell transistor are electrically connected to each other.

Abstract: A neuromorphic device is provided. The neuromorphic device may include a pre-synaptic neuron; a row line extending in a row direction from the pre-synaptic neuron; a post-synaptic neuron; a column line extending in a column direction from the post-synaptic neuron; and a synapse disposed at an intersection between the row line and the column line. The synapse may include a first synapse layer including a plurality of first carbon nano-tubes; a second synapse layer including a plurality of second carbon nano-tubes having different structures from the plurality of first carbon nano-tubes; and a third synapse layer including a plurality of third carbon nano-tubes having different structures from the plurality of first carbon nano-tubes and the plurality of second carbon nano-tubes.

Abstract: The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.